Table 1.
Different nanomaterials of various dimensions for POC biosensing for health and wellness.
| Dimensionality | Name of nanomaterial | POC detection of | Limit of detection | Ref. |
|---|---|---|---|---|
| 0D (Nanoparticle) | Au@SCX8-RGO-TB | SARS-CoV-2 | 200 RNA copies/mL | Zhao et al. (2021) |
| 0D (Nanoparticle) | Colloidal gold | Human papilloma virus (HPV) | 1000 copies/μL | Ma et al. (2019) |
| 0D (Quantum dot) | Quantum dot | High-sensitivity cardiac troponin (hs-cTn) | 0.04 ng/mL (critical value) | Zhou et al. (2019) |
| 0D (Nanoparticle) | Fe2O3 Nanoparticles | Ovarian cancer ctRNA | 1 fM | Gorgannezhad et al. (2018) |
| 0D (Nanoparticle) | Gold Nanoparticle | Glucose | 0.1 mM | Xuan et al. (2018) |
| 0D (Quantum dot) | Graphene quantum dots (GQD) | Cephalexin | 0.53 fM | Kolhe et al. (2023) |
| 0D (Nanoparticle) | Gold Nanoparticle | Aflatoxin M1(carcinogen) | 3 pM | Kasoju et al. (2020a) |
| 0D (Nanoparticle) | Gold Nanoparticle | Aflatoxin B1(carcinogen) | 10 nM | Kasoju et al. (2020b) |
| 0D (Nanoparticle) | Gold Nanoparticle | Aflatoxin B1(carcinogen) | 33 fg/mL | Li et al. (2021) |
| 1D (Nanowire) | Gold Nanowire | Alzheimer's disease (miRNA-137) | 1.7 fM | Azimzadeh et al. (2017) |
| 1D (Nanowire) | Gold Nanowire | Parkinson's disease (miRNA-195) | 2.9 fM | Aghili et al. (2017) |
| 1D (Nanorod) | Gold Nanorod | Glucose | 0.8 mM | Tao et al. (2021) |
| 1D (Nanorod) | Gold Nanorod | SARS-CoV-2 RBD antigen | 0.73 fM | Shahdeo et al. (2022) |
| 1D (Nanorod) | Gold Nanorod | Japanese Encephalitis Virus (JEV) | 0.36 nM | Roberts et al. (2022b) |
| 2D (Nanosheet) | Graphene | Zika virus (NS1 antigen) | 450 pM | Afsahi et al. (2018) |
| 2D (Nanosheet) | Graphene oxide | Cardiac biomarker BNP (brain natriuretic peptide) | 100 fM | Lei et al. (2017) |
| 2D (Nanosheet) | Reduced graphene oxide | Patulin (PAT) | 0.66 nM | Shukla et al. (2020) |
| 2D (Nanosheet) | Graphene oxide | 4T1 breast cancer cells | 100 cells/mL | Zhang et al. (2016) |
| 2D (Nanosheet) | Graphene oxide | Lung cancer miRNA | 0.87 fM | Khoothiam et al. (2019) |
| 2D (Nanosheet) | Reduced graphene oxide | Prostate specific antigen (PSA) | 10 pg/mL | Wei et al. (2018) |
| 2D (Nanosheet) | Graphene | DNA mutations for Duchenne muscular dystrophy | 1.7 fM | Hajian et al. (2019) |
| 2D (Nanosheet) | Graphene | Folic acid protein (FAP) | 5 fM | He et al. (2017) |
| 2D (Metal organic framework) | Cobalt metal-organic framework | Glucose | 16.3 μM | (al Lawati and Hassanzadeh, 2020) |
| 2D (Metal organic framework) | Metal organic framework | carcinoembryonic antigen (CEA) | 0.742 pg/mL | Zeng et al. (2022) |
| 2D (Nanosheet) | Nickel metal-organic framework 2D nanosheet | Peroxidase | 8 nM | Chen et al. (2018) |
| 3D (Metal organic framework) | zeolitic imidazole framework-90 (ZIF-90) | Adenosine triphosphate | 233 nM | Cao et al. (2022) |
| 3D (Metal organic framework) | lanthanide functionalized metal organic framework | Glucose | 0.2 μM | Zhang and Yan (2019) |
| 3D (Metal organic framework) | Copper-Metal organic framework (Cu-MOF) | Glucose | 0.11 μM | Lu et al. (2020) |
| 3D (Metal organic framework) | Copper-Metal organic framework (Ni-MOF) | Glucose | 0.25 μM | Xiao et al. (2017) |
| 3D (Metal organic framework) | Cobalt-Metal organic framework (Co-MOF) | Glucose | 1.6 μM | Zhang et al. (2020) |